Tìm theo
Lenalidomide
Các tên gọi khác (7 ) :
  • 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
  • 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • CC-5013
  • CDC 501
  • IMid-1
  • IMiD3
  • Revlimid
Thuốc điều trị ung thư
Thuốc Gốc
Small Molecule
CAS: 191732-72-6
ATC: L04AX04
ĐG : Celgene , http://www.celgene.com
CTHH: C13H13N3O3
PTK: 259.2606
Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C13H13N3O3
Phân tử khối
259.2606
Monoisotopic mass
259.095691297
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChI Key
InChIKey=GOTYRUGSSMKFNF-UHFFFAOYSA-N
IUPAC Name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
Traditional IUPAC Name
lenalidomide
SMILES
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Độ hòa tan
Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.
logP
-0.4
logS
-2
pKa (strongest acidic)
11.61
pKa (Strongest Basic)
2.31
PSA
92.5 Å2
Refractivity
68.3 m3·mol-1
Polarizability
25.55 Å3
Rotatable Bond Count
1
H Bond Acceptor Count
4
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
3
Bioavailability
1
Rule of Five
true
Dược Lực Học : Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.
Cơ Chế Tác Dụng : Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005. The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity
Dược Động Học :
▧ Absorption :
Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.
▧ Protein binding :
30% protein bound.
▧ Metabolism :
Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.
▧ Route of Elimination :
Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.
▧ Half Life :
Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.
▧ Clearance :
The renal clearance of lenalidomide exceeds the glomerular filtration rate.
Độc Tính : The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
Chỉ Định : Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Tương Tác Thuốc :
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Capsule - Oral - 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Revlimid 5 mg capsule
    Giá bán buôn : USD >388.0
    Đơn vị tính : capsule
  • Biệt dược thương mại : Revlimid 10 mg capsule
    Giá bán buôn : USD >406.05
    Đơn vị tính : capsule
  • Biệt dược thương mại : Revlimid 15 mg capsule
    Giá bán buôn : USD >407.7
    Đơn vị tính : capsule
  • Biệt dược thương mại : Revlimid 25 mg capsule
    Giá bán buôn : USD >411.71
    Đơn vị tính : capsule
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Ladevina
  • Công ty :
    Sản phẩm biệt dược : Lenangio
  • Công ty : Celegene
    Sản phẩm biệt dược : Revlimid
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00480
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=216326
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505725
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D04687
ChemSpider
http://www.chemspider.com/Chemical-Structure.187515.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50078323
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/59572-410-00
PharmGKB
http://www.pharmgkb.org/drug/PA162363968
Wikipedia
http://en.wikipedia.org/wiki/Lenalidomide
RxList
http://www.rxlist.com/revlimid-drug.htm
Drugs.com
http://www.drugs.com/cdi/lenalidomide.html
... loading
... loading